- Home
- AGEN vs UONE Comparison
AGEN vs UONE Comparison
Compare AGEN & UONE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- UONE
- Stock Information
- Founded
- AGEN 1994
- UONE 1980
- Country
- AGEN United States
- UONE United States
- Employees
- AGEN N/A
- UONE N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- UONE Broadcasting
- Sector
- AGEN Health Care
- UONE Consumer Discretionary
- Exchange
- AGEN Nasdaq
- UONE Nasdaq
- Market Cap
- AGEN 52.6M
- UONE 68.4M
- IPO Year
- AGEN 2000
- UONE N/A
- Fundamental
- Price
- AGEN $2.91
- UONE $1.64
- Analyst Decision
- AGEN Buy
- UONE
- Analyst Count
- AGEN 4
- UONE 0
- Target Price
- AGEN $8.00
- UONE N/A
- AVG Volume (30 Days)
- AGEN 830.5K
- UONE 28.9K
- Earning Date
- AGEN 05-12-2025
- UONE 05-13-2025
- Dividend Yield
- AGEN N/A
- UONE N/A
- EPS Growth
- AGEN N/A
- UONE N/A
- EPS
- AGEN N/A
- UONE N/A
- Revenue
- AGEN $103,463,000.00
- UONE $449,674,000.00
- Revenue This Year
- AGEN $4.03
- UONE N/A
- Revenue Next Year
- AGEN $5.57
- UONE N/A
- P/E Ratio
- AGEN N/A
- UONE N/A
- Revenue Growth
- AGEN N/A
- UONE N/A
- 52 Week Low
- AGEN $1.38
- UONE $1.23
- 52 Week High
- AGEN $19.69
- UONE $3.33
- Technical
- Relative Strength Index (RSI)
- AGEN 59.81
- UONE 65.21
- Support Level
- AGEN $2.87
- UONE $1.38
- Resistance Level
- AGEN $3.16
- UONE $1.70
- Average True Range (ATR)
- AGEN 0.35
- UONE 0.11
- MACD
- AGEN 0.02
- UONE 0.02
- Stochastic Oscillator
- AGEN 56.25
- UONE 84.29
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About UONE Urban One Inc.
Urban One Inc is an urban oriented, multi-media company. Its business is radio broadcasting franchise that is the radio broadcasting operation that targets African-American and urban listeners. It operates through the following segments: Radio Broadcasting, Reach Media, Digital, and Cable Television. The Radio Broadcasting segment includes all the broadcasting related operations. The Reach Media segment consists of the Tom Joyner Morning Show and its related activities. The Digital segment focuses on its online business, including the operations of Interactive One. The Cable Television segment deals with TV One's operations.